
Investors
Information Disclosure
-
VOLUNTARY ANNOUNCEMENT - ACCEPTANCE OF NEW INDICATION APPLICATION FOR MARKETING OF CULMERCICLIB CAPSULE FOR FIRST-LINE TREATMENT OF BREAST CANCER2025.07.10
-
VOLUNTARY ANNOUNCEMENT - "RECOMBINANT HUMAN COAGULATION FACTOR VIIA N01 FOR INJECTION" APPROVED FOR MARKETING2025.07.03
-
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 JUNE 20252025.07.02
-
VOLUNTARY ANNOUNCEMENT - INDICATION OF ANLOTINIB HYDROCHLORIDE CAPSULES IN COMBINATION WITH CHEMOTHERAPY FOR FIRST-LINE TREATMENT OF SOFT TISSUE SARCOMA APPROVED FOR MARKETING2025.06.30
-
VOLUNTARY ANNOUNCEMENT - NEW INDICATION OF LM-108 ("CCR8 MONOCLONAL ANTIBODY") INCLUDED IN BREAKTHROUGH THERAPY DESIGNATION PROCESS2025.06.26
-
VOLUNTARY ANNOUNCEMENT - PRECLINICAL AND CLINICAL DATA ON ROVADICITINIB PRESENTED AT EHA 20252025.06.18
-
VOLUNTARY ANNOUNCEMENT - NEW INDICATION OF TDI01 SUSPENSION (“ROCK2 INHIBITOR”) INCLUDED IN BREAKTHROUGH THERAPY DESIGNATION PROCESS BY CDE2025.06.16
-
VOLUNTARY ANNOUNCEMENT - THE LATEST PROGRESS OF INNOVATION-DRIVEN DEVELOPMENT OF THE GROUP2025.06.13